Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;102(10):1101-1108.
doi: 10.1038/s41374-022-00804-9. Epub 2022 May 20.

Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer

Myrto Moutafi  1   2 , Charles J Robbins  1 , Vesal Yaghoobi  1 , Aileen I Fernandez  1 , Sandra Martinez-Morilla  1 , Vasiliki Xirou  1 , Yalai Bai  1 , Yan Song  1 , Patricia Gaule  1 , Joseph Krueger  3 , Kenneth Bloom  3 , Salisha Hill  4 , Daniel C Liebler  4 , Regan Fulton  5 , David L Rimm  6   7
Affiliations
Free article

Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer

Myrto Moutafi et al. Lab Invest. 2022 Oct.
Free article

Abstract

The efficacy of the antibody drug conjugate (ADC) Trastuzumab deruxtecan (T-DXd) in HER2 low breast cancer patients suggests that the historical/conventional assays for HER2 may need revision for optimal patient care. Specifically, the conventional assay is designed to distinguish amplified HER2 from unamplified cases but is not sensitive enough to stratify the lower ranges of HER2 expression. Here we determine the optimal dynamic range for unamplified HER2 detection in breast cancer and then redesign an assay to increase the resolution of the assay to stratify HER2 expression in unamplified cases. We used the AQUA™ method of quantitative immunofluorescence to test a range of antibody concentrations to maximize the sensitivity within the lower range of HER2 expression. Then, using a cell line microarray with HER2 protein measured by mass spectrometry we determined the amount of HER2 protein in units of attomols/mm2. Then by calculation of the limits of detection, quantification, and linearity of this assay we determined that low HER2 range expression in unamplified cell lines is between 2 and 20 attomol/mm2. Finally, application of this assay to a serial collection of 364 breast cancer cases from Yale shows 67% of the population has HER2 expression above the limit of quantification and below the levels seen in HER2 amplified breast cancer. In the future, this assay could be used to determine the levels of HER2 required for response to T-DXd or similar HER2 conjugated ADCs.

PubMed Disclaimer

References

    1. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med 2018; 142: 1364–1382; e-pub ahead of print 2018/05/31; https://doi.org/10.5858/arpa.2018-0902-SA .
    1. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659–2671; https://doi.org/10.1200/JCO.1998.16.8.2659 .
    1. Howie LJ, Scher NS, Amiri-Kordestani L, Zhang L, King-Kallimanis BL, Choudhry Y, et al. FDA Approval summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer. Clin Cancer Res 2019; 25: 2949–2955; e-pub ahead of print 2018/12/16; https://doi.org/10.1158/1078-0432.Ccr-18-3003 .
    1. Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008 13: 1114–1119; e-pub ahead of print 2008/10/14; https://doi.org/10.1634/theoncologist.2008-0816 .
    1. Koleva-Kolarova RG, Oktora MP, Robijn AL, Greuter MJW, Reyners AKL, Buskens E, et al. Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treat Rev 2017; 55: 16–25; https://doi.org/10.1016/j.ctrv.2017.01.001 .

Publication types